RECURSION PHARMACEUTICALS, INC. Other-than-temporary Impairment Loss, Debt Securities, Available-for-sale
RECURSION PHARMACEUTICALS, INC. (RXRX) reported Other-than-temporary Impairment Loss, Debt Securities, Available-for-sale of $0 for the 3-month period ending 2022-06-30, per its 10-Q filed 2022-08-09.
Discontinued › Expense Statement › Operating Expenses
us-gaap:OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale · last filed 2022-08-09
- RECURSION PHARMACEUTICALS, INC. other-than-temporary impairment loss, debt securities, available-for-sale for the quarter ending 2022-06-30 was $0.00.
- RECURSION PHARMACEUTICALS, INC. other-than-temporary impairment loss, debt securities, available-for-sale for the quarter ending 2022-03-31 was $0.00.
- RECURSION PHARMACEUTICALS, INC. other-than-temporary impairment loss, debt securities, available-for-sale for the quarter ending 2021-12-31 was $0.00.
- RECURSION PHARMACEUTICALS, INC. other-than-temporary impairment loss, debt securities, available-for-sale for the quarter ending 2021-09-30 was $0.00.
- RECURSION PHARMACEUTICALS, INC. other-than-temporary impairment loss, debt securities, available-for-sale for fiscal 2021 was $0.00.
| Period end | Other-than-temporary Impairment Loss, Debt Securities, Available-for-sale 3 month | Other-than-temporary Impairment Loss, Debt Securities, Available-for-sale 6 month | Other-than-temporary Impairment Loss, Debt Securities, Available-for-sale 9 month | Other-than-temporary Impairment Loss, Debt Securities, Available-for-sale 12 month |
|---|---|---|---|---|
| 2022-06-30 | $0.00 10-Q · filed 2022-08-09 | $0.00 10-Q · filed 2022-08-09 | $0.00 derived: sum of 3 quarters · filed 2022-08-09 | $0.00 derived: sum of 4 quarters · filed 2022-08-09 |
| 2022-03-31 | $0.00 10-Q · filed 2022-05-10 | $0.00 derived: sum of 2 quarters · filed 2022-05-10 | $0.00 derived: sum of 3 quarters · filed 2022-05-10 | |
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-23 | $0.00 derived: sum of 2 quarters · filed 2022-03-23 | $0.00 10-K · filed 2022-03-23 | |
| 2021-09-30 | $0.00 10-Q · filed 2021-11-10 | $0.00 10-Q · filed 2021-11-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| BIOCRYST PHARMACEUTICALS INC (BCRX) | United States | $2.175B | -6.63 |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 | |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |